Loading...
•
Jun 30, 2022
Esperion Q2 2022 Earnings Report
Esperion's financial performance reflected revenue growth and advancements in clinical trials.
Key Takeaways
Esperion reported Q2 2022 financial results, with total revenue of $18.8 million, a decrease of 54% compared to Q2 2021. U.S. product revenue grew 28% year-over-year to $13.6 million. The CLEAR Outcomes trial reached 100% MACE accumulation, and topline results are expected in Q1 2023.
Total revenue was $18.8 million, a 54% decrease compared to the same period in 2021.
U.S. product revenue increased by 28% year-over-year, reaching $13.6 million.
The CLEAR Outcomes trial achieved 100% of the targeted MACE-4 accumulation.
Topline results from the CLEAR Outcomes trial are on track for the first quarter of 2023.
Esperion
Esperion
Esperion Revenue by Segment
Revenue by Segment
U.S. Net Product Revenue
CapyFin.comCollaboration Revenue
CapyFin.com Forward Guidance
Esperion reaffirmed its full-year 2022 operational expense guidance. Research and Development expenses for the full year 2022 are expected to be $100 million to $110 million. Selling, General and Administrative expenses for the full year 2022 are expected to be $120 million to $130 million.
Positive Outlook
- Research and Development expenses for the full year 2022 are expected to be $100 million to $110 million.
- Selling, General and Administrative expenses for the full year 2022 are expected to be $120 million to $130 million.
- Esperion expects full-year 2022 operating expenses to be approximately $220 million to $240 million.
- Operating expense guidance includes $25 million of non-cash, stock-based compensation expense.
- The company reaffirming its prior operational expense guidance.
Revenue & Expenses
Visualization of income flow from segment revenue to net income